VISTA-GROUP
10.4.2018 18:52:03 CEST | Business Wire | Press release
Vista Entertainment Solutions (Vista Cinema), the leading provider of cinema management software for the global cinema exhibition market, has completed the rollout for its first customer in Italy, The Space Cinema, which operates 36 cinemas with 362 screens. The Space Cinema is part of Vue International.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180410006322/en/
Vista Group Chief Executive Kimbal Riley describes the rollout as a fantastic achievement. “This was a challenging regulatory process in a new territory for Vista and builds on the strong relationship we have with Vue International. It’s a great testament to our excellent local partners that we’ve been able to complete this rollout.”
Managing Director, Europe, Middle East and Africa at Vista Entertainment Solutions, Mischa Kay says: “Together with the fantastic team at The Space Cinema, we have successfully rolled out a broad selection of the Vista Cinema software suite across the Italian circuit. Italy is a top 20 cinema-going market and represents a significant opportunity not only for Vista Cinema, but for the Vista Group as a whole, to provide business benefits to the Italian industry.”
“Vue International continues to implement best practices across its group of circuits in Europe,” says Roland Jones, Executive Director, Technical Services, Vue International. “We are pleased to have extended our relationship with Vista, with whom we have worked extensively in the UK for many years. By introducing Vista’s state-of-the-art, integrated operating system to cinemas such as The Space, we maximize a host of benefits that only the leading global cinema system can deliver.”
The Managing Director of The Space Cinema, Toby Bradon, has also welcomed the completion of the rollout: “On behalf of The Space Cinema, we are very pleased to be the first Italian circuit working with Vista. Following a rapid and successful implementation we look forward to maximising the benefits of Vista’s modern, class-leading cinema operating system. Working in conjunction with our colleagues at Vue International, The Space Cinema continues to invest in its customer experience supporting our mission to be the first choice in cinema entertainment in Italy.”
About The Space Cinema:
The Space Cinema is a leading cinema operator in Italy with 36 multiplex cinemas and 362 screens. Space owns five out of the top ten highest grossing cinemas in Italy including the No.1 grossing cinema in the Italian market - Parco de Medici. The business is a leader in a fragmented cinema market. At the end of 2014, The Space Cinema was acquired by Vue Entertainment International.
About Vue International
Vue International is one of the world's leading cinema operators,
managing the most respected brands in major European markets and Taiwan,
spanning ten countries, 212 sites and 1,902 screens. The group has
leading positions in the United Kingdom, Ireland, Germany, Denmark,
Netherlands, Italy, Poland, Latvia, Lithuania and Taiwan. From its
inception in May 2003 Vue International has grown organically and
through strategic acquisition to deliver a premium out-of-home
entertainment experience by combining the best content, with the best
technology in the best environment.
Website: www.myvue.com/about-us
About Vista Group International:
Vista Group International (Vista Group) is a public company, listed on
both the New Zealand and Australian stock exchanges (NZX & ASX: VGL).
The Group provides software and additional technology solutions across
the global film industry. Cinema management software is provided by
Vista Entertainment Solutions (Vista Cinema), the core business of the
Group. Movio (authority in moviegoer data analytics), Veezi (cloud-based
SaaS software for the Independent Cinema Market), movieXchange
(connecting the movie industry to simplify the promotion and sale of
movie tickets), Maccs (film distribution software), Numero (box office
reporting software for film distributors and cinemas), Cinema
Intelligence (business intelligence solutions), Powster (creative studio
and marketing platform for movie studios) and Flicks (moviegoer ‘go to’
portal for movie information) provide an innovative range of
complementary products across additional film industry sectors, from
production and distribution, to cinema exhibition through to the
moviegoer experience. Vista Group has offices located in New Zealand
(Auckland HQ), Sydney, Los Angeles, London, Shanghai, Beijing, Mexico
City, South Africa, the Netherlands and Romania.
Website: www.vistagroup.co
LinkedIn:
www.linkedin.com/company/vista-group-limited
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410006322/en/
Contact:
Media Contacts:
For Vista Group International/NZ & EUROPE
Christine
Fenby
+64 21 727 006
christine.fenby@vista.co
or
For
Vista Group International/USA
Maggie Begley/MBC
+1 310 390
0101
maggie@mbcprinc.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom